🚀 VC round data is live in beta, check it out!
Scilex Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Scilex Holding and similar public comparables like Vicapsys, SCYNEXIS, Labiana Health, Rein Therapeutics and more.
Scilex Holding Overview
About Scilex Holding
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Founded
2009
HQ
Employees
115
Website
Sectors
Financials (LTM)
EV
$161M
Scilex Holding Financials
Scilex Holding reported last 12-month revenue of $46M.
In the same LTM period, Scilex Holding generated $34M in gross profit and had net loss of ($253M).
Revenue (LTM)
Scilex Holding P&L
In the most recent fiscal year, Scilex Holding reported revenue of $38M and EBITDA of ($358M).
Scilex Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $46M | XXX | $38M | XXX | XXX | XXX |
| Gross Profit | $34M | XXX | $20M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($358M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (953%) | XXX | XXX | XXX |
| EBIT Margin | (411%) | XXX | (664%) | XXX | XXX | XXX |
| Net Profit | ($253M) | XXX | ($342M) | XXX | XXX | XXX |
| Net Margin | (549%) | XXX | (910%) | XXX | XXX | XXX |
| Net Debt | — | — | $104M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Scilex Holding Stock Performance
Scilex Holding has current market cap of $48M, and enterprise value of $161M.
Market Cap Evolution
Scilex Holding's stock price is $6.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $161M | $48M | 3.9% | XXX | XXX | XXX | $-48.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialScilex Holding Valuation Multiples
Scilex Holding trades at 3.5x EV/Revenue multiple, and (0.5x) EV/EBITDA.
EV / Revenue (LTM)
Scilex Holding Financial Valuation Multiples
As of April 19, 2026, Scilex Holding has market cap of $48M and EV of $161M.
Equity research analysts estimate Scilex Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scilex Holding has a P/E ratio of (0.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $48M | XXX | $48M | XXX | XXX | XXX |
| EV (current) | $161M | XXX | $161M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | (0.9x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | 8.2x | XXX | XXX | XXX |
| P/E | (0.2x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 52.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Scilex Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Scilex Holding Margins & Growth Rates
Scilex Holding's revenue in the last 12 month grew by 123%.
Scilex Holding's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $2.5M for the same period.
Scilex Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 123% | XXX | 76% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (953%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 436% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.5M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 34% | XXX | 55% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 777% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Scilex Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Scilex Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Vicapsys | XXX | XXX | XXX | XXX | XXX | XXX |
| SCYNEXIS | XXX | XXX | XXX | XXX | XXX | XXX |
| Labiana Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Rein Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Xilio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scilex Holding M&A Activity
Scilex Holding acquired XXX companies to date.
Last acquisition by Scilex Holding was on XXXXXXXX, XXXXX. Scilex Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Scilex Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialScilex Holding Investment Activity
Scilex Holding invested in XXX companies to date.
Scilex Holding made its latest investment on XXXXXXXX, XXXXX. Scilex Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Scilex Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Scilex Holding
| When was Scilex Holding founded? | Scilex Holding was founded in 2009. |
| Where is Scilex Holding headquartered? | Scilex Holding is headquartered in United States. |
| How many employees does Scilex Holding have? | As of today, Scilex Holding has over 115 employees. |
| Who is the CEO of Scilex Holding? | Scilex Holding's CEO is Henry Ji. |
| Is Scilex Holding publicly listed? | Yes, Scilex Holding is a public company listed on Nasdaq. |
| What is the stock symbol of Scilex Holding? | Scilex Holding trades under SCLX ticker. |
| When did Scilex Holding go public? | Scilex Holding went public in 2022. |
| Who are competitors of Scilex Holding? | Scilex Holding main competitors are Vicapsys, SCYNEXIS, Labiana Health, Rein Therapeutics. |
| What is the current market cap of Scilex Holding? | Scilex Holding's current market cap is $48M. |
| What is the current revenue of Scilex Holding? | Scilex Holding's last 12 months revenue is $46M. |
| What is the current revenue growth of Scilex Holding? | Scilex Holding revenue growth (NTM/LTM) is 123%. |
| What is the current EV/Revenue multiple of Scilex Holding? | Current revenue multiple of Scilex Holding is 3.5x. |
| Is Scilex Holding profitable? | No, Scilex Holding is not profitable. |
| What is the current net income of Scilex Holding? | Scilex Holding's last 12 months net income is ($253M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.